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BACKGROUND: Differences in the breast cancer burden of African-American women compared with white Ameri-
can women are well documented. Recent controversies have emerged regarding age-appropriate mammographic
screening guidelines, and these surveillance recommendations may influence future breast cancer disparities. The
objective of the current study was to evaluate age-specific breast cancer stage distributions and incidence rates
of triple-negative breast cancer (TNBC) in a population-based tumor registry. METHODS: The authors analyzed
breast cancers from the California Cancer Registry (CCR) that were diagnosed between 1988 and 2006. The results
were stratified by age and race/ethnicity, with white Americans identified as non-Hispanic whites (NHWs) and
African Americans identified as non-Hispanic blacks (NHBs). Breast cancer stage distributions and TNBC incidence
rates also were analyzed. RESULTS: In total, 375,761 invasive breast cancers were evaluated (including 276,938 in
NHWs and 21,681 in NHBs). NHBs and Hispanics tended to be younger than NHWs (median ages 57 years, 54 years,
and 64 years, respectively). Lifetime incidence rates were higher for NHWs compared with NHBs and Hispanics;
however, for women aged <44 years, incidence was highest among NHBs. NHBs also had higher incidence rates of
stage III and IV disease and a higher incidence of TNBC in all age categories. CONCLUSIONS: Population-based
data demonstrated that African-American women had a more advanced stage distribution for breast cancer com-
pared with white American women and higher incidence rates for TNBC. These patterns were observed for women
ages 40 to 49 years and for older women, and they suggest that mammographic screening for the early detection of
breast cancer will be particularly relevant for younger African-American women. Cancer 2011;117:2747–53. VC 2011
American Cancer Society.
More than 200,000 women are diagnosed with breast cancer each year in the United States, and it is projected that
approximately 40,000 will die with the disease annually.1 Breast cancer mortality rates have declined over the past 20 m
years in the United States, and this improvement in outcome is largely explained by the combination of earlier detection
and screening mammography coupled with the use of more effective systemic therapy.2 Systemic therapy options for
breast cancer are determined by the molecular marker expression of individual tumors. Therefore, the best outcomes are
observed for cancers that are either detected early (ie, when the distant organ micrometastatic risk is low) or that have a
marker pattern indicating a high likelihood of controlling micrometastases with targeted treatment, such as endocrine
therapy for hormone receptor-positivite tumors and/or trastuzumab for tumors with human epidermal growth factor
receptor 2 (HER2/neu) overexpression. Conversely, tumors that are detected at an advanced stage or that are negative for
these markers are more likely to be associated with breast cancer mortality.
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Population-based data regarding the breast cancer
burden of different subsets of the American female popula-
tion have revealed several interesting (albeit incompletely
understood) patterns. Most notably, African-American
women have a lower lifetime risk of breast cancer, but
their mortality rates are paradoxically higher compared
with the rates among white American women.1 The age-
incidence curves also differ; among women aged <45
years, the incidence rates are higher for African Americans
compared with white Americans. Furthermore, the fre-
quency of breast tumors that are negative for the estrogen
receptor (ER), the progesterone receptor (PR), and/or the
HER2/neumarker also is increased among African-American
women.3
Breast cancer screening with annual mammography
beginning at age 40 years has been advocated since the
mid-1990s by organizations such as the American Cancer
Society, the American College of Surgeons, and the
National Comprehensive Cancer Network. This recom-
mendation was challenged recently by the US Preventive
Services Task Force (USPSTF), which issued a published
statement in November 2009 in support of deferring the
initiation of mammography screening until age 50 years.4
Presumably, this screening strategy could have a dispro-
portionately adverse effect on women who face an
increased risk of being diagnosed with early onset breast
cancer, advanced-stage disease, and/or biologically more
aggressive tumors. The objective of this project was to
assess the potential implications of the USPSTF recom-
mendation relative to African-American women by com-
puting age-specific, population-based stage distributions
for breast cancer as well as age-specific incidence rates of
triple-negative breast cancer (TNBC). For these analyses,
we relied on data from the population-based California
Cancer Registry (CCR), which has provided valuable
information regarding disparities in breast cancer related
to racial/ethnic identity since 1988.5-8
MATERIALS AND METHODS
An analysis of CCR data from 1988 to 2006 was per-
formed. Age-adjusted and age-specific invasive breast can-
cer incidence rates for the 3 major race/ethnic groups
(non-Hispanic white [NHW], non-Hispanic black
[NHB], and Hispanic) were computed using data from
the CCR. The CCR is a population-based cancer registry
that has monitored cancer incidence and mortality in Cal-
ifornia since 1988. The SEER*Stat software program
(version 6.5.2; National Cancer Institute; Surveillance,
Epidemiology, and End Results [SEER] Program,
Bethesda, Md) was used to analyze the CCR database,
including 95% confidence intervals.9 Statistical signifi-
cance testing was based on chi-square comparisons for
categorical variables, and the Student t test was used to
compare the mean values of continuous variables. P values
<.05 were considered statistically significant.
The CCR database for breast cancer was analyzed
according to disease stage at diagnosis (according to the
American Joint Committee on Cancer Cancer Staging
Manual, seventh edition) and stratified by age (catego-
rized as ages <40 years, 40 to 49 years, 50 to 59 years, 60
to 74 years, and 75 years); then, comparisons were eval-
uated with respect to the racial/ethnic subsets of the Cali-
fornia population. Racial/ethnic identity was assigned by
self-report as documented by the tumor registries that
contribute to the CCR program.
Staging information and positive versus negative
hormone receptor (ER and PR) status also was assigned
according to the information contributed by the CCR
registrars. For HER2/neu expression, positive or negative
status was based on documented immunohistochemistry
and/or fluorescence in situ hybridization analysis. Statis-
tics for TNBC incidence rates were limited to women
who were diagnosed beginning in 2004. Documentation
of HER2/neu status appeared to be more uniform and
complete during this latter interval, when clinical trial
results regarding the effectiveness of adjuvant trastuzumab
for HER2/neu-overexpressing breast cancers were more
widely available; therefore, this component of molecular
marker information became more relevant on a routine
basis for all women who were diagnosed with invasive
breast cancer.10,11
RESULTS
In total, 375,761 women were newly diagnosed with inva-
sive breast cancer as reported in the CCR from 1988 to
2006. Of these, there were 278,241 NHW women
(74%), 21,716 NHB women (5.8%), and 45,523 His-
panic women (12.1%).
The median age at diagnosis was 64 years, 57 years,
and 54 years for NHW, NHB, and Hispanic patients,
respectively. The median age at diagnosis for patients with
unknown racial/ethnic background was 61.5 years. The
age-incidence rates listed in Table 1 and the age-incidence
curves in Figure 1 demonstrate that the risk of breast can-
cer rose with increasing age for all racial/ethnic subsets
that we evaluated. Figure 1 also indicates that, among
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women aged <44 years, population-based incidence rates
of breast cancer were highest for NHBwomen; for women
aged >44 years, the incidence rates were highest for
NHW women. Incidence rates were lowest for Hispanic
women in all age categories. Incidence rates of stage I and
II breast cancer were lower for NHB women compared
with NHW women in all age categories; however, inci-
dence rates for stages III and IV disease were higher for
NHB women. Breast cancer incidence rates for any stage
generally were lower for Hispanics women compared with
NHWwomen in all age categories.
Figure 2 illustrates the incidence rates by disease
stage for the study population subsets and demonstrates
the shift toward more frequent detection of advanced-
stage disease (stages III and IV) for NHB women com-
pared with NHW and Hispanic women. Figure 3 indi-
cates that most of the rising breast cancer incidence rates
associated with increasing age were a consequence of
increasing risk of non-TNBC. Incidence rates for TNBC
were <50 per 100,000 population (for all race-ethnic
groups combined) in all age categories, but these rates
slowly rose with age and plateaued beyond the fifth decade
of life.
Table 2 and Figure 4 demonstrate the increased risk
of TNBC for NHB women in all age categories. The inci-
dence of TNBC rose more steeply with increasing age for
NHB women compared with NHW and Hispanic
women, and those incidence rates were approximately
Table 1. California Cancer Registry Breast Cancer Incidence Rates by Stage and Age Category Among Non-Hispanic White,
Non-Hispanic Black, and Hispanic Women Diagnosed During 1988 to 2006a



















<40 3.6 3.5 3.7 3299 2.9 2.6 3.2 393 1.8 1.6 1.9 967
40-49 60.7 59.7 61.7 14,969 40.1 37.8 42.4 1194 30.3 29.2 31.4 3043
50-59 130.5 128.9 132.2 24,576 75.5 71.7 79.4 1508 60 58.1 62 3545
60-74 221.9 219.9 223.9 46,806 122.5 117.4 127.6 2245 106.3 103.4 109.3 5114
‡75 210.6 208.2 213 29,303 115.6 108.6 122.9 1013 100 95.7 104.6 1972
Stage II
<40 5.6 5.4 5.7 5166 6.3 5.9 6.8 860 4.5 4.3 4.6 2502
40-49 65.9 64.9 67 16,238 63.4 60.6 66.4 1895 47.9 46.5 49.2 4839
50-59 104.5 103.1 106 19,622 95.1 90.8 99.5 1897 68.2 66.1 70.4 4033
60-74 138.6 137 140.2 29,170 111 106.2 116 2033 84.7 82.1 87.3 4122
‡75 134.1 132.2 136.1 18,855 111.2 104.3 118.4 976 86.5 82.5 90.8 1698
Stage III
<40 1.2 1.2 1.3 1131 1.9 1.7 2.1 255 1.4 1.3 1.5 795
40-49 13.1 12.6 13.5 3213 18.5 17 20.1 552 12.8 12.1 13.5 1298
50-59 20 19.3 20.6 3745 26.7 24.5 29.1 532 18.4 17.3 19.5 1087
60-74 21.7 21.1 22.4 4566 26.9 24.6 29.4 496 18.6 17.4 19.8 908
‡75 26.2 25.4 27.1 3745 34.9 31.1 39 307 20.3 18.3 22.4 396
Stage IV
<40 0.5 0.4 0.5 433 0.9 0.8 1.1 124 0.5 0.4 0.5 275
40-49 5.5 5.2 5.8 1350 8.8 7.8 10 263 4.4 4 4.8 440
50-59 11.4 10.9 11.9 2149 17.3 15.5 19.2 345 8 7.3 8.7 472
60-74 17.3 16.8 17.9 3648 23.5 21.4 25.9 431 12.5 11.5 13.5 605
‡75 19 18.3 19.7 2695 25.6 22.4 29.2 225 12.8 11.2 14.4 249
NA/unstaged
<40 2 1.9 2.1 1817 3 2.7 3.3 406 1.7 1.6 1.8 973
40-49 21.4 20.8 22 5266 27 25.2 28.9 806 16.4 15.6 17.2 1659
50-59 37 36.2 37.9 6961 43.3 40.4 46.3 864 26.3 25 27.6 1553
60-74 69.8 68.7 70.9 14,740 68 64.3 72 1238 39 37.3 40.8 1889
‡75 102.5 100.9 104.2 14,778 97 90.9 104 858 56.2 52.9 59.7 1089
CI indicates confidence interval; NA, not available.
a Rates are per 100,000 and were age-adjusted to the US 2000 standard population (19 age groups; US Census Bureau. Current Population Reports: P25-1130
Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050. Washington, DC: US Census Bureau; 1996). CIs (Tiwari modifi-
cation) are 95% for rates. Based on the January 2010 release of California Cancer Registry incidence data, National Center for Health Statistics estimates.
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2-fold higher for NHB women compared with either of
the other subsets in the groups ages 40 to 49 years and 50
to 59 years. The TNBC incidence rates peaked at 64.4 per
100,000 NHBwomen in the group ages 60 to 74 years.
DISCUSSION
Recent challenges to the traditional recommendations
that American women initiate annual screening mam-
mography at age 40 years have the potential for exerting a
disproportionately adverse effect on African-American
women because of the well documented younger age dis-
tribution for breast cancer in this population subset. Early
detection of breast cancer is the most powerful determi-
nant of outcome, and this will be particularly relevant for
tumors that express phenotypes that cannot be controlled
with targeted agents, such as endocrine therapy and/or
trastuzumab. African-American women have higher mor-
tality rates from breast cancer, and this is explained at least
partially by the finding that they tend to present with
more advanced stages compared with white American
women. Therefore, they represent a community that has
been the focus of many breast cancer awareness and
screening/early detection programs. Our current study
provides further evidence of the need to continue inten-
sive breast cancer surveillance among African-American
women ages 40 to 49 years. By studying data from the
CCR, we observed higher population-based incidence
rates of locally advanced breast cancer and TNBC among
African-American women.
Although the lifetime incidence rates of breast can-
cer are higher for white American women compared with
African-American women, the SEER Program documents
that, for women aged <45 years, population-based inci-
dence rates are higher for African Americans.12 Several
investigators have demonstrated that the frequency of
TNBC is higher for African-American patients with
breast cancer compared their white American counter-
parts.13-16 Furthermore, Carey et al17 demonstrated that
the risk of TNBC was particularly high among premeno-
pausal African-American women based on an analysis of
the Carolina Breast Cancer Study. By reporting on age-
specific and race/ethnicity-specific patterns of disease in
Figure 1. Age-specific breast cancer incidence rates are illus-
trated for women who were aged <50 years at diagnosis
according to race/ethnicity from the California Cancer Regis-
try. Note that crossover in the age-incidence curves between
non-Hispanic (NH) whites and NH blacks occurred in the
group ages 40 to 44 years (arrow), and the incidence rates
were higher among younger NH blacks.
Figure 2. Age-adjusted incidence rates of breast cancer
among women are illustrated according to race/ethnicity
and disease stage at diagnosis from the California Cancer
Registry. NH indicates non-Hispanic.
Figure 3. Triple-negative breast cancer (TNBC) incidence
rates compared to incidence rates of all other breast cancers
(BC). Incidence rates per 100,000 are illustrated by age from
the California Cancer Registry.
Original Article
2750 Cancer June 15, 2011
the CCR, our study current provides powerful popula-
tion-based evidence regarding the importance of aggres-
sive screening for the early detection of breast cancer in
young African-American women.
Reviews of data from the historic mammography
screening trials were prepared by Nelson et al18 and Man-
delblatt et al on behalf of the Cancer Intervention and
Surveillance Modeling Network (CISNET)19 as back-
ground for the updated screening guidelines presented by
the USPSTF in November 2009.4 In summary, those
investigators reported that, for women ages 40 to 49 years,
approximately 1900 must be invited to mammographic
screening to save 1 life; for women ages 50 to 59 years,
approximately 1300 must be invited; and, for women ages
60 to 69 years, approximately 400 must be invited. Those
reviewers also observed that the initiation of mammog-
raphy screening at age 40 years rather than age 50 years
resulted in an average gain of 33 life years per 1000
women screened. The CISNET authors commented that
if the goal of a national screening program is to reduce
mortality in the most efficient manner, then programs
that screen biennially beginning at age 50 years are among
the most efficient based upon the ratio of benefits to the
number of screening examinations. CISNET also noted
that, if the objective of the screening program is to maxi-
mize the number of life-years gained, then initiation of
screening at age 40 years would be the preferred strat-
egy.19 The USPSTF opted to advocate in favor of sup-
porting an efficiency-based screening model rather than a
longevity-based program and they published a statement
advising against routine screening mammography in aver-
age-risk women ages 40 to 49 years but recommended in
favor of screening mammography every 2 years for women
ages 50 to 74 years.4 The CISNET authors also com-
mented that none of the mammography screening models
were likely to capture differences in outcome among spe-
cific population subsets, ‘‘such as women with BRCA1 or
BRCA2 genetic susceptibility mutations, women who are
healthier or sicker than average, or black women who
seem to have more disease at younger ages than white
women.’’19 The USPSTF recommendation statement
however, did not comment on the potential impact of
their screening recommendations on race-ethnicity-asso-
ciated breast cancer disparities.
Our study serves to inform the discussion regarding
the relevance of mammography screening for African-
American women ages 40 to 49 years. We observed that
there was more advanced-stage disease at diagnosis in these
younger African-American women, and we also observed
higher incidence rates of TNBC for this population subset.
Because mammography screening programs should
improve early detection rates for breast cancer, and because
the early detection of TNBC is critical for improving
Table 2. Triple-Negative Breast Cancer Incidence Rates per 100,000 by Age and Race From the California Cancer Registrya
NHB NHW Hispanic
Age, y Incidence Rate 95% CI Incidence Rate 95% CI Incidence Rate 95% CI
0-39 4.1  0.4 3.4-5.0 2.2  -0.1 2.0-2.5 2.1  0.1 1.9-2.3
40-49 35.1  2.2 31-39.6 16.8  0.6 15.7-17.9 15.1  0.7 13.7-16.5
50-59 54.9  3.2 48.9-61.5 27.7  0.8 26.2-29.2 24.9  1.1 22.7-27.2
60-74 64.4  3.8 57.1-72.4 36.3  0.9 34.6-38.2 26.4  1.4 23.8-29.3
75 49.9  4.8 40.9-60.4 30.3  1.0 28.3-32.3 19.3  1.7 16.1-23.0
NHB indicates non-Hispanic black; NHW, non-Hispanic white; CI, confidence interval.
aMeanstandard deviation rates are per 100,000 US 2000 standard population. Confidence intervals (Tiwari modification) are 95% for rates.
Figure 4. Triple-negative breast cancer incidence rates from
the California Cancer Registry are shown by age and race
(rates are per 100,000 and were age-adjusted to the 2000
US standard population [19 age groups; US Census Bureau.
Current Population Reports: P25-1130 Population Projections
of the United States by Age, Sex, Race, and Hispanic Origin:
1995 to 2050. Washington, DC: US Census Bureau; 1996]).
Confidence intervals (Tiwari modification) are 95% for rates.
NH indicates non-Hispanic.
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likelihood of its successful treatment, we believe that our
current findings provide compelling evidence that screen-
ing mammography is particularly important for young
African-American women. The USPSTF recommenda-
tion that routine screening mammography should not be
initiated until age 50 years has the potential for widening
the magnitude of breast cancer outcome disparities
between African-American and white American women.
The CCR data on race/ethnicity-associated frequency
of TNBC is consistent with other studies, as indicated in
Table 3. The population-based incidence rates featured in
our study serve to strengthen the validity of these observa-
tions. These rates indicate an inherently higher risk of
TNBC for NHB/African-American women, refuting the
argument that the larger proportion of TNBC in African-
American women is an artifact of the ‘‘denominator’’ phe-
nomenon (ie, African-American women appear to have
more TNBC simply because they have fewer total breast
cancers compared with white American women). Our data
on women from California demonstrate an increased
population-based risk of TNBC for NHBwomen.
This study is limited by our unfortunate inability to
correlate mammography screening information with the
age-specific and race/ethnicity-specific breast cancer inci-
dence rates. Although the data regarding effectiveness of
mammography in detecting TNBC (compared with
detection rates for non-TNBC) are limited, the available
published studies indicate that the frequency of mammo-
graphically occult breast tumors is similar for TNBC and
non-TNBC. However, TNBC appears to be associated
less frequently with microcalcifications and is more likely
to be identified as a mass or asymmetric density.20-23 Fur-
thermore, Ma et al demonstrated that mammographic
density (a common imaging finding among premeno-
pausal women) is a risk factor for both TNBC and non-
TNBC.24
Another noteworthy limitation of our current study
is that the CCR (similar to the SEER Program) lacks
detailed information on menstrual history and reproduc-
tive factors. Millikan et al25 and other investigators26 have
suggested that childbearing patterns and lactation history
may account for race/ethnicity-associated variation in
breast cancer burden, although others have been unable to
confirm those hypotheses.27 Other investigators have
reported an elevated risk of TNBC among contemporary
populations of women in continental Africa,28-30 suggest-
ing that African ancestrymay be associated with some herit-
able risk factor for TNBC.31 Our population-based
California dataset was unable to address any of these issues.
In summary, our data from California (which
appear to be representative of national data) demonstrate
an increased risk of advanced-stage breast cancer and
TNBC for African-American women compared with
white American and Hispanic-American women. These
patterns are notably prominent for women aged <50
years, suggesting that mammography screening to
improve the early detection of biologically aggressive pat-
terns of breast cancer is particularly relevant for younger
African-American women.
CONFLICT OF INTEREST DISCLOSURES
The collection of cancer incidence data used in this study was
supported by the California Department of Public Health as
part of the statewide cancer reporting program mandated by
Table 3. Published Studies of Estrogen Receptor-Negative/Progesterone Receptor-Negative/Human Epidermal Growth Factor




Study Dataset Sample Size Dataset AA WA P
Carey 200617 Carolina Breast Cancer Study 97 Premenopausal AA women;
164 premenopausal WA women
39 16 <.001
Morris 200713 Thomas Jefferson University Hospital
patients; SEER Program
2230 Thomas Jefferson University Hospital
patients; 197,274 SEER patients
21% 10 <.001
Lund 200915 Population-based cohort from Atlanta, Ga 116 AA patients; 360 WA patients 47 22 <.001
Lund 200814 Grady Hospital; Atlanta, Ga 167 AA; 23 WA 29 13 .05
Moran 200816 BCS patients from Yale University
School of Medicine
99 AA; 968 WA 21 8 <.001
Parise 20095 California Cancer Registry 3743 AA; 48,863 WA 28 12 NR
Stark 201030 Henry Ford Hospital, Detroit, Mich 1008 WA; 581 AA 16 26 <.01
TNBC indicates triple-negative breast cancer; AA, African American; WA, white American; SEER, Surveillance, Epidemiology, and End Results; BCS, breast-
conservation surgery; NR, not reported.
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California Health and Safety Code Section 103885; by the
National Cancer Institute’s Surveillance, Epidemiology, and End
Results Program under contract N01-PC-35136 awarded to the
Northern California Cancer Center, contract N01-PC-35139
awarded to the University of Southern California, and contract
N01-PC-54404 awarded to the Public Health Institute; and by
the Centers for Disease Control and Prevention’s National Pro-
gram of Cancer Registries under agreement 1U58DP00807-01
awarded to the Public Health Institute.
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